Tools
Stock profile

VERTEX PHARMACEUTICALS INC / MA (VRTX)

VRTX · Latest close $536.45 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$536.45
As of Nov 18, 2026
Tracked funds holding
4 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
4
vs previous quarter

VERTEX PHARMACEUTICALS INC / MA (VRTX) is held by 4 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 4 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $15.4M sold). 0 members of Congress reported 0 purchases vs 1 sale. Latest close $536.45 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 16, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-15.4M
Congress
0 buys vs 1 sale
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Edgewood Management · Tweedy Browne · Torray Investment Partners LLC — 4 tracked funds hold VRTX. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 4 sales ($15.4M). Insider trading 0 members of Congress reported buying (0 purchases vs 1 sale). Politician trading

Often held alongside

Bank of New York Mellon Corp (BNY) · AbbVie Inc. (ABBV) · NEXTERA ENERGY INC (NEE) · AMPHENOL CORP /DE/ (APH) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Edgewood Management2.72%531,003TRIMMED (-41.3%) Q3 filed Nov 12
Tweedy Browne1.51%40,121TRIMMED (-0.7%) Q3 filed Nov 4
Torray Investment Partners LLC1.02%15,215TRIMMED (-1.1%) Q3 filed Oct 30
Harding Loevner0.01%1,163TRIMMED (-99.6%) Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +7.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

558.88358.852024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding1,748 of 8,857 filers
Long-only filers among them1,741
Change vs 2026 Q1+85 net · 1,417 entered · 1,332 exited
Shares reported, all filers239,716,267
Reported value, all filers$117.6B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$12.0B
Net income · FY2025$4.0B
Total assets · FY2025$25.6B
Shares outstanding253,460,924
Market cap (at latest close)$136.0B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 20264,263,331
Share of shares outstanding1.68%
Days to cover3.39

Shares short at recent settlements — Jul 31, 2026: 3.9M · Aug 14, 2026: 4.1M · Aug 31, 2026: 4.7M · Sep 15, 2026: 4.7M · Sep 30, 2026: 4.5M · Oct 15, 2026: 4.3M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 2026424
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 2026<0.1%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 3 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 424.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 4 sales by 4 insiders ($15.4M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 16, 2026Thornberry NancySell1,000$547.86$547.9KSEC filing
Nov 16, 2026Bhatia Sangeeta N.Sell271$547.86$148.5KSEC filing
Nov 12, 2026WAGNER CHARLES F JREVP, CO & FOSell15,286$547.87$8.4MSEC filing
Nov 6, 2026Kewalramani ReshmaCEO & PresidentSell11,866$531.53$6.3MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Aug 27, 2026Bruce I. SachsDirector1,210$662.5KAug 27, 2026SEC filing
Jul 2, 2026Tatsis OuraniaOfficer1,500$787.5KJul 2, 2026SEC filing
Jul 2, 2026McKechnie DuncanOfficer1,541$799.8KJul 2, 2026SEC filing
Jul 1, 2026Liu JoyOfficer828$416.2KJul 1, 2026SEC filing
Jun 26, 2026Bozic CarmenOfficer596$287.6KJun 26, 2026SEC filing
Jun 18, 2026Bozic CarmenOfficer1,020$471.4KJun 18, 2026SEC filing
Jun 15, 2026Bozic CarmenOfficer4,062$1.8MJun 15, 2026SEC filing
Jun 5, 2026Bozic CarmenOfficer1,745$785.2KJun 5, 2026SEC filing
Jun 1, 2026Liu JoyOfficer828$364.2KJun 1, 2026SEC filing
May 29, 2026Bozic CarmenOfficer1,974$888.3KMay 29, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 14, 2026Capital World InvestorsSC 13G/A25,695,01510.1%Mar 31, 2026SEC filing
May 14, 2026Capital Research Global InvestorsSC 13G/A21,139,1698.3%Mar 31, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G19,036,0767.5%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 12, 2026Capital Research Global InvestorsSC 13G/A17,319,0446.8%Dec 31, 2025SEC filing
May 13, 2025Capital Research Global InvestorsSC 13G14,536,3445.7%Mar 31, 2025SEC filing
Feb 13, 2025Capital World InvestorsSC 13G/A28,739,97511.2%Dec 31, 2024SEC filing
Feb 12, 2025FMR LLCSC 13G/A9,220,826.783.6%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

0 members of Congress reported buying (0 purchases vs 1 sale).

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Taylor, David J.HouseR01Aug 26, 2026$1,001 - $15,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

Financial Screens

· Growth — Revenue up every year for 5 straight years

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Growth — Latest revenue: $12.0B · 5-yr revenue CAGR: 14.1% · Straight growth years: 9

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 2 of the last 20 quarterly lists; latest 2025 Q3, ranked #41 of 50.

Also held by the tracked funds that hold VRTX — ranked by lift, the co-holding pattern described in Methodology: Bank of New York Mellon Corp (BNY) · AbbVie Inc. (ABBV) · NEXTERA ENERGY INC (NEE) · AMPHENOL CORP /DE/ (APH).

Filings audit: every filing lens on VERTEX PHARMACEUTICALS INC / MA (VRTX), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Nov 2, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 20, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain OfficersSEC filing
Sep 1, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain OfficersSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Bank of New York Mellon Corp (BNY) · Filings audit: every filing lens on VERTEX PHARMACEUTICALS INC / MA (VRTX), scored · Practice timing on VRTX

One email a week: the week’s new filings and research. Subscribe free

← VRT  ·  VSAT →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.